Medscape EDUCATION

INCLUSION BODY MYOSITIS

Authors: Rohit Aggarwal, MD, MS; Elie Naddaf, MD

Supported by an independent educational grant from Abcuro, Inc.

Target Audience and Goal Statement

This activity is intended for an audience of neurologists, rheumatologists, physical medicine and rehabilitation specialists, nurse practitioners, physician assistants, and nurses.

The goal of this activity is for learners to be better able to summarize the impact of inclusion body myositis (IBM) symptoms on patients' quality of life (QOL).

Learning Objectives

Upon completion of this activity, participants will:

- Have increased knowledge regarding the
  - Symptoms of IBM
  - Impact of IBM symptoms on patients' and caregivers' QOL

Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Rohit Aggarwal, MD, MS
Rohit Aggarwal, MD, MS
Professor of Medicine
Co-Director, UPMC Myositis Center
Program Director, UPMC Myositis Fellowship Program
University of Pittsburgh School of Medicine
Pittsburgh, Pennyslvania

Rohit Aggarwal, MD, MS, has the following relevant financial relationships:
Consultant or advisor for: Alexion; ANI Pharmaceuticals; Argenx; Artasome; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Company; CabalettaBio; Capella Bioscience; Capstanx; Corbus; CSL Behring; EMD Serono; Galapagos; Horizon Therapeutics; I-Cell; Immunovant; Janssen; Kezar; Kyverna; Lilly; Manta Medicines Corporation; Novartis; Nuvig Therapeutics; Nkarta; Octapharma; Pfizer Inc.; PRoivant; Teva; Tourmaline Bio; Verismo Therapeutics
Research funding from: Boehringer Ingelheim; Bristol-Myers Squibb Company; EMD Serono; Janssen; Pfizer Inc.; PRoivant

Elie Naddaf, MD
Associate Professor of Neurology
Mayo Clinic,
Rochester, Minnesota

Elie Naddaf, MD, has the following relevant financial relationships:
Consultant or advisor for: Johnson and Johnson (former)
Research funding from: Abcuro; Cabaletta; Fulcrum

Editor

Lisette Arnaud-Hevi, PhD
Senior Medical Education Director, Medscape, LLC
Lisette Arnaud-Hevi, PhD, has no relevant financial relationships.

Peer Reviewer
This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Disclaimer

- The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.
- The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.
- Medscape Education © 2025 Medscape, LLC